Association between BDNF Gene Polymorphisms and Serotonergic Activity Using Loudness Dependence of Auditory Evoked Potentials in Healthy Subjects

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Park, Young Min ^a,b   Lee, Seung Hwan ^a,b   Lee, Heon Jeong ^c   Kang, Seung Gul ^d   Min, Jung Ah ^e   Chae, Jeong Ho ^e  

^a Inje University   (South Korea)

^b Clinical Emotion and Cognition Research Laboratory   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; ARTICLE; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; EVOKED AUDITORY RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; KOREAN; LOUDNESS DEPENDENCE OF AUDITORY EVOKED POTENTIAL; MALE; NORMAL HUMAN; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; EVOKED POTENTIALS, AUDITORY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LOUDNESS PERCEPTION; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN; YOUNG ADULT;

EID: 84876026195     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060340     Document Type: Article

References (46)

1. Hegerl U, Juckel G, (1993) Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 33: 173-187.
2. Juckel G, Molnar M, Hegerl U, Csepe V, Karmos G, (1997) Auditory-evoked potentials as indicator of brain serotonergic activity-first evidence in behaving cats. Biol Psychiatry 41: 1181-1195.
3. Strobel A, Debener S, Schmidt D, Hunnerkopf R, Lesch KP, et al. (2003) Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. Am J Med Genet B Neuropsychiatr Genet 118B: 41-47.
4. Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, et al. (2003) Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. Schizophr Res 64: 115-124.
5. Gudlowski Y, Ozgurdal S, Witthaus H, Gallinat J, Hauser M, et al. (2009) Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity. Schizophr Res 109: 141-147.
6. Park YM, Lee SH, Kim S, Bae SM, (2010) The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 34: 313-316.
7. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, et al. (2000) The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 148: 404-411.
8. Hegerl U, Gallinat J, Juckel G, (2001) Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62: 93-100.
9. Juckel G, Pogarell O, Augustin H, Mulert C, Muller-Siecheneder F, et al. (2007) Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry 68: 1206-1212.
10. Linka T, Muller BW, Bender S, Sartory G, (2004) The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett 367: 375-378.
11. Park YM, Kim DW, Kim S, Im CH, Lee SH, (2011) The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder. Psychopharmacology (Berl) 213: 625-632.
12. Park YM, Lee SH, Park EJ, (2012) Usefulness of LDAEP to predict tolerability to SSRIs in major depressive disorder: a case report. Psychiatry Investig 9: 80-82.
13. Autry AE, Monteggia LM, (2012) Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 64: 238-258.
14. Altar CA, Boylan CB, Fritsche M, Jackson C, Hyman C, et al. (1994) The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp Neurol 130: 31-40.
15. Calabrese F, Molteni R, Maj PF, Cattaneo A, Gennarelli M, et al. (2007) Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 32: 2351-2359.
16. Nibuya M, Morinobu S, Duman RS, (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539-7547.
17. Nibuya M, Nestler EJ, Duman RS, (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16: 2365-2372.
18. Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, et al. (2007) Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 32: 2152-2162.
19. Lang UE, Hellweg R, Gallinat J, (2005) Association of BDNF serum concentrations with central serotonergic activity: evidence from auditory signal processing. Neuropsychopharmacology 30: 1148-1153.
20. Juckel G, Schumacher C, Giegling I, Assion HJ, Mavrogiorgou P, et al. (2010) Serotonergic functioning as measured by the loudness dependence of auditory evoked potentials is related to a haplotype in the brain-derived neurotrophic factor (BDNF) gene. J Psychiatr Res 44: 541-546.
21. First MB (1997) User's guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version. Washington, DC: American Psychiatric Press. 132 p. p.
22. First MB (1997) User's guide for the structured clinical interview for DSM-IV axis II personality disorders: SCID-II. Washington, DC: American Psychiatric Press, Inc. 41 p. p.
23. Oliva JL, Leung S, Croft RJ, O'Neill BV, Stout JC, et al. (2011) Evidence for sex differences in the loudness dependence of the auditory evoked potential in humans. Hum Psychopharmacol 26: 172-176.
24. Semlitsch HV, Anderer P, Schuster P, Presslich O, (1986) A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 23: 695-703.
25. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ, (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123B: 19-22.
26. Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, et al. (2007) The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 21: 650-656.
27. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS, (2006) Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118: 176-182.
28. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, et al. (2008) Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 9: 1595-1603.
29. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, et al. (2010) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 20: 535-544.
30. Juckel G, Mavrogiorgou P, Bredemeier S, Gallinat J, Frodl T, et al. (2004) Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders- a retrospective study. Pharmacopsychiatry 37: 46-51.
31. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, et al. (2010) Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 15: 810-815.
32. Beuten J, Ma JZ, Payne TJ, Dupont RT, Quezada P, et al. (2005) Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. Am J Med Genet B Neuropsychiatr Genet 139B: 73-80.
33. Qian L, Zhao J, Shi Y, Zhao X, Feng G, et al. (2007) Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem Biophys Res Commun 353: 738-743.
34. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, et al. (2011) Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 26: 1-10.
35. Real E, Gratacos M, Soria V, Escaramis G, Alonso P, et al. (2009) A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol Psychiatry 66: 674-680.
36. Cidis Meltzer C, Drevets WC, Price JC, Mathis CA, Lopresti B, et al. (2001) Gender-specific aging effects on the serotonin 1A receptor. Brain Res 895: 9-17.
37. Hagenmuller F, Hitz K, Darvas F, Kawohl W, (2011) Determination of the loudness dependence of auditory evoked potentials: single-electrode estimation versus dipole source analysis. Hum Psychopharmacol 26: 147-154.
38. Yu H, Wang DD, Wang Y, Liu T, Lee FS, et al. (2012) Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci 32: 4092-4101.
39. Liebl DJ, Tessarollo L, Palko ME, Parada LF, (1997) Absence of sensory neurons before target innervation in brain-derived neurotrophic factor-, neurotrophin 3-, and TrkC-deficient embryonic mice. J Neurosci 17: 9113-9121.
40. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, et al. (1999) Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96: 15239-15244.
41. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, et al. (2004) Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 101: 10827-10832.
42. Chourbaji S, Hellweg R, Brandis D, Zörner B, Zacher C, etl al, (2004) Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 121: 28-36.
43. Djalali S, Höltje M, Grosse G, Rothe T, Stroh T, et al. (2005) Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem 92: 616-627.
44. Oliva JL, Leung S, Croft RJ, O'Neill BV, Stout JC, et al. (2011) Evidence for sex differences in the loudness dependence of the auditory evoked potential in humans. Hum Psychopharmacol 26: 172-176.
45. Min JA, Lee SH, Lee SY, Chae JH, Lee CU, et al. (2012) Clinical characteristics associated with different strengths of loudness dependence of auditory evoked potentials (LDAEP) in major depressive disorder. Psychiatry Res 200: 374-381.
46. Linka T, Sartory G, Bender S, Gastpar M, Muller BW, et al. (2007) The intensity dependence of auditory ERP components in unmedicated patients with major depression and healthy controls. An analysis of group differences. J Affect Disord 103: 139-145.